Skip to content

PRP Prevents Recurrence of Intrauterine Adhesions

Platelet-rich Plasma(PRP) Prevents Recurrence of Intrauterine Adhesions

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03629132
Acronym
RPR-IUAs
Enrollment
60
Registered
2018-08-14
Start date
2018-08-15
Completion date
2019-12-30
Last updated
2018-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Adhesion

Brief summary

Effect of platelet-rich plasma (PRP) on uterine scar fibrosis, endometrial receptivity and pregnancy outcome in patients with severe intrauterine adhesions

Detailed description

1. Inclusion criteria: patients with intrauterine adhesions (AFS score \>9 points); age 21 to 40 years old, with fertility requirements. 2. Study design:prospective, randomized controlled cohort study, patients with intrauterine adhesions were randomized into two groups, the control group and the intervention group (intraoperative and postoperative 1 week postoperative PRP). The surgical procedures and postoperative medication regimens were the same. 3. Compare the biochemical pregnancy rate, clinical pregnancy rate, abortion rate and live birth rate after hysteroscopic resection in PRP group and control group, and explore the effect of PRP on pregnancy outcome after intrauterine adhesion.

Interventions

PROCEDUREPlatelet-rich plasma

Platelet-rich plasma intrauterine injection

PROCEDUREgel

Self-crosslinking sodium hyaluronate gel intrauterine injection

Sponsors

Yanhong Deng
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

Patients with intrauterine adhesions (AFS score \>9 points); age 21 to 40 years old, with fertility requirements -

Exclusion criteria

Endometrial tuberculosis, endometrial polyps, uterine submucosal fibroids, endometrial hyperplasia, endometrial malignant lesions, premature ovarian failure, chromosomal abnormalities \-

Design outcomes

Primary

MeasureTime frameDescription
AFS score1 yearAFS score

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026